发布求助
文献互助 智能选刊 最新文献

Clinical Lymphoma, Myeloma & Leukemia最新文献

筛选
英文 中文
OA-55 Iberdomide, Daratumumab, and Dexamethasone (IberDd) in Transplant-Ineligible (TNE) Newly Diagnosed Multiple Myeloma (NDMM): Results From the CC-220-MM-001 Trial OA-55伊博多肽、达拉单抗和地塞米松（IberDd）治疗不符合移植条件（TNE）的新诊断多发性骨髓瘤（NDMM）：CC-220-MM-001试验结果
IF 2.7 4区 医学
Clinical Lymphoma, Myeloma & Leukemia Pub Date : 2024-09-01 DOI: 10.1016/S2152-2650(24)01896-2
{"title":"OA-55 Iberdomide, Daratumumab, and Dexamethasone (IberDd) in Transplant-Ineligible (TNE) Newly Diagnosed Multiple Myeloma (NDMM): Results From the CC-220-MM-001 Trial","authors":"","doi":"10.1016/S2152-2650(24)01896-2","DOIUrl":"10.1016/S2152-2650(24)01896-2","url":null,"abstract":"","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142309745","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
OA-61 All Oral Triplet Iberdomide Ixazomib and Dexamethasone in Elderly Patients With Multiple Myeloma Patients at First Relapse: Results of the IFM Phase 2 Study I2D OA-61 全口服三联伊贝多米-伊沙佐米和地塞米松治疗首次复发的老年多发性骨髓瘤患者：IFM 2 期研究 I2D 的结果
IF 2.7 4区 医学
Clinical Lymphoma, Myeloma & Leukemia Pub Date : 2024-09-01 DOI: 10.1016/S2152-2650(24)01902-5
{"title":"OA-61 All Oral Triplet Iberdomide Ixazomib and Dexamethasone in Elderly Patients With Multiple Myeloma Patients at First Relapse: Results of the IFM Phase 2 Study I2D","authors":"","doi":"10.1016/S2152-2650(24)01902-5","DOIUrl":"10.1016/S2152-2650(24)01902-5","url":null,"abstract":"","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142310921","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
OA-41 Evaluation of the IMWG 2/20/20 IMWG SMM Risk Stratification Model in a Cohort of Patients Evaluated With Modern Imaging OA-41 评估 IMWG 2/20/20 IMWG SMM 风险分层模型在现代成像评估患者队列中的应用
IF 2.7 4区 医学
Clinical Lymphoma, Myeloma & Leukemia Pub Date : 2024-09-01 DOI: 10.1016/S2152-2650(24)01882-2
{"title":"OA-41 Evaluation of the IMWG 2/20/20 IMWG SMM Risk Stratification Model in a Cohort of Patients Evaluated With Modern Imaging","authors":"","doi":"10.1016/S2152-2650(24)01882-2","DOIUrl":"10.1016/S2152-2650(24)01882-2","url":null,"abstract":"","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142311868","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
P-025 Real-world outcomes of teclistamab for the treatment of relapsed/refractory multiple myeloma at UC San Diego Health: A single-institution experience P-025 加州大学圣地亚哥分校医疗中心使用替卡单抗治疗复发/难治性多发性骨髓瘤的实际效果：单一机构经验
IF 2.7 4区 医学
Clinical Lymphoma, Myeloma & Leukemia Pub Date : 2024-09-01 DOI: 10.1016/S2152-2650(24)01928-1
{"title":"P-025 Real-world outcomes of teclistamab for the treatment of relapsed/refractory multiple myeloma at UC San Diego Health: A single-institution experience","authors":"","doi":"10.1016/S2152-2650(24)01928-1","DOIUrl":"10.1016/S2152-2650(24)01928-1","url":null,"abstract":"","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142311795","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
OA-19 Marrow Immune Features Are Most Informative of Early MRD Negative Treatment Response in Newly Diagnosed TE Patients: Insights from the UKMRA Phase 3 RADAR Study OA-19 骨髓免疫特征对新诊断的 TE 患者的早期 MRD 阴性治疗反应最有参考价值：UKMRA第3期RADAR研究的启示
IF 2.7 4区 医学
Clinical Lymphoma, Myeloma & Leukemia Pub Date : 2024-09-01 DOI: 10.1016/S2152-2650(24)01860-3
{"title":"OA-19 Marrow Immune Features Are Most Informative of Early MRD Negative Treatment Response in Newly Diagnosed TE Patients: Insights from the UKMRA Phase 3 RADAR Study","authors":"","doi":"10.1016/S2152-2650(24)01860-3","DOIUrl":"10.1016/S2152-2650(24)01860-3","url":null,"abstract":"","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142311711","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
P-018 Updated Comparative Effectiveness of Talquetamab vs Real-World Physician's Choice of Treatment in LocoMMotion and MoMMent for Patients With Triple-Class Exposed Relapsed/Refractory Multiple Myeloma P-018 塔奎单抗与真实世界中医生选择的治疗方法在三类暴露的复发性/难治性多发性骨髓瘤患者中的最新疗效比较（LocoMMotion and MoMMent
IF 2.7 4区 医学
Clinical Lymphoma, Myeloma & Leukemia Pub Date : 2024-09-01 DOI: 10.1016/S2152-2650(24)01921-9
{"title":"P-018 Updated Comparative Effectiveness of Talquetamab vs Real-World Physician's Choice of Treatment in LocoMMotion and MoMMent for Patients With Triple-Class Exposed Relapsed/Refractory Multiple Myeloma","authors":"","doi":"10.1016/S2152-2650(24)01921-9","DOIUrl":"10.1016/S2152-2650(24)01921-9","url":null,"abstract":"","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142312054","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
P-011 Impact of Daratumumab Refractoriness on Clinical Outcomes Following CAR T-cell Therapy for Relapsed/Refractory Multiple Myeloma P-011 达拉单抗难治性对复发/难治性多发性骨髓瘤 CAR T 细胞疗法临床结果的影响
IF 2.7 4区 医学
Clinical Lymphoma, Myeloma & Leukemia Pub Date : 2024-09-01 DOI: 10.1016/S2152-2650(24)01914-1
{"title":"P-011 Impact of Daratumumab Refractoriness on Clinical Outcomes Following CAR T-cell Therapy for Relapsed/Refractory Multiple Myeloma","authors":"","doi":"10.1016/S2152-2650(24)01914-1","DOIUrl":"10.1016/S2152-2650(24)01914-1","url":null,"abstract":"","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142312156","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
P-001 Impact of Age and Frailty on Outcomes of Patients with Multiple Myeloma Receiving CAR T-Cell Therapies – A Single Center Experience P-001 年龄和体弱对接受 CAR T 细胞疗法的多发性骨髓瘤患者预后的影响--单中心经验
IF 2.7 4区 医学
Clinical Lymphoma, Myeloma & Leukemia Pub Date : 2024-09-01 DOI: 10.1016/S2152-2650(24)01904-9
{"title":"P-001 Impact of Age and Frailty on Outcomes of Patients with Multiple Myeloma Receiving CAR T-Cell Therapies – A Single Center Experience","authors":"","doi":"10.1016/S2152-2650(24)01904-9","DOIUrl":"10.1016/S2152-2650(24)01904-9","url":null,"abstract":"","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142312247","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
P-003 Determinants of Response to Anti-CD38 and Bispecific Combination Therapy in Patients with Relapsed/Refractory Multiple Myeloma P-003 多发性骨髓瘤复发/难治患者对抗CD38和双特异性联合疗法反应的决定因素
IF 2.7 4区 医学
Clinical Lymphoma, Myeloma & Leukemia Pub Date : 2024-09-01 DOI: 10.1016/S2152-2650(24)01906-2
{"title":"P-003 Determinants of Response to Anti-CD38 and Bispecific Combination Therapy in Patients with Relapsed/Refractory Multiple Myeloma","authors":"","doi":"10.1016/S2152-2650(24)01906-2","DOIUrl":"10.1016/S2152-2650(24)01906-2","url":null,"abstract":"","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142312249","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
OA-24 A Novel Mouse Model Engineered With Human Immune System Is a Translationally-Important Model for Studies Related to Immune-Microenvironment and Immunotherapies in Multiple Myeloma OA-24 利用人类免疫系统设计的新型小鼠模型是多发性骨髓瘤免疫微环境和免疫疗法相关研究的重要转化模型
IF 2.7 4区 医学
Clinical Lymphoma, Myeloma & Leukemia Pub Date : 2024-09-01 DOI: 10.1016/S2152-2650(24)01865-2
{"title":"OA-24 A Novel Mouse Model Engineered With Human Immune System Is a Translationally-Important Model for Studies Related to Immune-Microenvironment and Immunotherapies in Multiple Myeloma","authors":"","doi":"10.1016/S2152-2650(24)01865-2","DOIUrl":"10.1016/S2152-2650(24)01865-2","url":null,"abstract":"","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142311584","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信